Black Diamond: Mapping allostery

Black Diamond debuts with plans to identify, target allosteric mutant oncogenes

Black Diamond Therapeutics Inc. emerged from stealth on Tuesday with a platform to mine and drug baskets of allosteric mutant oncogenes using troves of human sequencing data that contain non-catalytic mutations previously deemed non-actionable. The company debuted with $20 million in a tranched series A round from Versant Ventures and represents the first start-up to launch from Versant’s Ridgeline incubator in Basel.

Allosteric mutations occur

Read the full 643 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE